^
    Back
    Association details:
    Biomarker:NRAS Q61K
    Cancer:Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Nat Med
    Title:

    Oncogenic NRAS Signaling Differentially Regulates Survival and Proliferation in Melanoma

    Excerpt:
    In the “iNRAS” GEM model of melanoma, expression of the melanoma signature mutation, NRASQ61K (or oncogenic NRAS)....in the NRAS-mutant human melanoma cell line HMVII, combined PD-0332991 and GSK1120212 treatment in xenograft tumors revealed synergistic anti-oncological efficacy (Fig. 5c).
    DOI:
    10.1038/nm.2941